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AbstrAct
Objectives to report on fatigue in patients from the 
United Kingdom primary Sjögren’s syndrome (pSS) registry 
identifying factors associated with fatigue and robust to 
assignable causes such as comorbidities and medications 
associated with drowsiness.
Methods From our cohort (n = 608), we identified those 
with comorbidities associated with fatigue, and those 
taking medications associated with drowsiness. We 
constructed dummy variables, permitting the contribution 
of these potentially assignable causes of fatigue to be 
assessed. Using multiple regression analysis, we modelled 
the relationship between Profile of Fatigue and Discomfort 
physical and mental fatigue scores and potentially related 
variables.
Results Pain, depression and daytime sleepiness 
scores were closely associated with both physical and 
mental fatigue (all p ≤ 0.0001). in addition, dryness was 
strongly associated with physical fatigue (p ≤ 0.0001). 
these effects were observed even after adjustment for 
comorbidities associated with fatigue or medications 
associated with drowsiness.
Conclusions these findings support further research and 
clinical interventions targeting pain, dryness, depression 
and sleep to improve fatigue in patients with pSS.
this finding is robust to both the effect of other 
comorbidities associated with fatigue and medications 
associated with drowsiness.
InTROduCTIOn
Primary Sjögren’s syndrome (pSS) is a 
chronic, systemic autoimmune disease 
characterised by functional impairment of 
the lachrymal and salivary glands. The disease 
can result in systemic involvement, which 
Key messages
What is already known about this subject?
 ► Patients with primary Sjögren’s syndrome (pSS) of-
ten report fatigue as the symptom most in need of 
improvement.
What does this study add?
 ► this study identifies pain, depression and daytime 
sleepiness scores as those factors most closely as-
sociated with both physical and mental fatigue in 
pSS.
 ► this finding is robust to both the effect of other co-
morbidities associated with fatigue and medications 
associated with drowsiness.
How might this impact on clinical practice?
 ► interventions directed at managing fatigue might 
be expected to have a significant impact on the pa-
tient’s quality of life.
 ► these findings support an interdisciplinary clinical 
assessment with:
 – an initial medication review,
 – assessment for comorbidities associated with 
fatigue,
 – screening for anxiety and depression,
 – assessment for undiagnosed sleep disorders,
 – pain management interventions and
 – interventions targeting fatigue management 
directly.
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may affect any organ, resulting in manifestations such 
as vasculitis, neuropathy, as well as skin, lung and kidney 
involvement.1 Patients with pSS often report fatigue as an 
important symptom in need of management.2 Defined as 
an overwhelming sense of tiredness, lack of energy and a feeling 
of exhaustion,3 4 fatigue is associated with poor health5 and 
functional impairment.6 Previous studies have shown that 
physical fatigue measured with the somatic component 
of the Profile of Fatigue scale (PROFAD)7 is more preva-
lent and severe in patients with pSS than mental fatigue 
as measured with the mental component of the same 
scale.7–9 Unsurprisingly, patients with pSS also report 
higher daytime sleepiness scores.9
For some patients with pSS, fatigue is likely to have an 
assignable cause other than pSS. For example, they may 
be taking medications associated with drowsiness, or have 
comorbidities associated with fatigue—including hypo-
thyroidism, depression, obesity, coeliac disease, diabetes 
and anaemia.
While there have been several previous studies exam-
ining the relationship between pSS, fatigue and other 
factors, these were conducted with lower numbers of 
patients and without regard to confounding medications 
or comorbidities. Furthermore, few studies have used the 
PROFAD which is a fatigue measure developed specifi-
cally for pSS.7
The objective of this paper is to report on the fatigue 
symptoms of a large cohort of 608 patients diagnosed with 
pSS defined using the American European Consensus 
Group (AECG) classification criteria and to identify 
factors associated with fatigue, and robust to assignable 
causes such as comorbidities and medications associated 
with fatigue.
MeTHOds
design
The United Kingdom primary Sjögren’s syndrome 
registry (UKPSSR, www. sjogrensregistry. org) is a proto-
col-driven, multicentre, cross-sectional study using stand-
ardised patient-reported measures and physician-gen-
erated assessments of patients with pSS from across the 
UK.10 All patients are participants in the UKPSSR and 
fulfil the AECG classification criteria. Note that fibromy-
algia was an explicit exclusion criterion for the UKPSSR. 
Informed consent was obtained from all participants 
according to the principles of the Helsinki Declaration. 
Research ethics approval was granted by the North West 
Research Ethics Committee in the UK. All clinical and 
laboratory data were collected prospectively using a stand-
ardised pro-forma at the time of recruitment as previously 
described.10 At the time of analysis, 639 patients had been 
recruited to UKPSSR and complete data were available 
for 608 patients.
Fatigue assessment
The Profile of Fatigue and Discomfort (PROFAD)7 was 
designed specifically for patients with pSS. It includes 
six questions which assess somatic and mental fatigue 
on an eight-point (0–7) scale. An average is taken for 
each domain score with a score of above 2.0 and 1.8 
being considered significant for the somatic fatigue and 
mental fatigue domains, respectively.7 8 The PROFAD 
also includes a 10 cm visual analogue score of fatigue, 
which provides a score of 0 for absent to 100 for worst 
imaginable perceived fatigue levels.
Pain, depression and other assessments of patients with pss
The following patient-reported outcome measures are 
collected for all UKPSSR pSS subjects: Epworth Sleepi-
ness Scale (EPWORTH), Hospital Anxiety and Depres-
sion Scale (HADs—anxiety and depression), Euro-
pean League Against Rheumatism (EULAR) Sjögren's 
syndrome Patient Reported Index (ESSPRI) (measure 
of overall symptom burden and includes a 1–10 pain 
score), EULAR Sicca Score (ESS) and EULAR Sjögren’s 
Syndrome Disease Activity Index (ESSDAI).
All UKPSSR participants are asked to indicate which 
symptom they perceive as being the most in need of 
improvement (physical fatigue, mental fatigue, dryness 
or pain). At the time of recruitment, the presence of 
anti-Ro and/or anti-La antibodies are recorded, as well 
as levels of systemic inflammation including C-reactive 
protein and erythrocyte sedimentation rate. Additionally, 
body mass index (BMI) and co-morbidities and medica-
tions are recorded for each participant.
We captured the effect of multiple drugs and comorbid-
ities using a comorbidity and polypharmacy score (CPS). 
This score is obtained by combining the number of comor-
bidities and the number of prescribed medications.11 To 
identify potentially assignable causes for fatigue in patients 
with pSS, we analysed our cohort for existing comorbidities 
and medication status. We classified the following comor-
bidities as conditions potentially associated with fatigue 
independently of pSS: hypothyroidism, diabetes mellitus 
(insulin-dependent diabetes mellitus (IDDM) and non-in-
sulin-dependent diabetes mellitus (NIDDM)), coeliac 
disease, anaemia (haemoglobin <10), a diagnosis of clinical 
depression and severe obesity (BMI ≥40).12 13 In addition, 
patients whose fatigue might be assignable to medications 
linked with drowsiness (eg, antidepressants, antipsychotics, 
opioids, etc) were identified—see online supplementary 
table S1. Using these data, we created dummy variables for 
each patient to adjust for medications associated with drows-
iness (DROWSY Medications) or comorbidities associated 
with fatigue (COMORBID).
statistical analysis
Multiple regression analysis was used to model the relation-
ships between physical and mental fatigue and candidate 
variables, including age, sex, pain, dryness, anxiety, depres-
sion, daytime sleepiness scores, BMI, symptom years, drowsy 
medications (DROWSY) and comorbidities (Anaemia 
COMORBID, Hypothyroidism COMORBID, IDDM 
COMORBID, NIDDM COMORBID, Obesity COMORBID, 
Depression COMORBID, Coeliac COMORBID). Causation 
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Table 1 Numbers of patients presenting with 
comorbidities. While 170 patients presented with one and 
22 presented with two or more comorbidities, most patients 
(416) presented with no comorbidities
Comorbidities
Number of 
patients
None 416
THYROID 114
COELIAC 16
DEPRESSION 16
DIABETES 10
OBESITY 8
THYROID+OBESITY 8
ANAEMIA 6
THYROID+DEPRESSION 3
THYROID+DIABETES 3
DIABETES+OBESITY 2
THYROID+ANAEMIA 2
DIABETES+DEPRESSION 1
ANAEMIA+COELIAC 1
THYROID+COELIAC 1
THYROID+DIABETES+OBESITY 1
Total 608
COMORBIDITIES Key: THYROID=hypothyroidism, 
COELIAC=coeliac disease, DEPRESSION=clinical 
depression diagnosis, DIABETES=IDDM or NIDDM diabetes, 
OBESITY=obesity, ANAEMIA=anaemia.
cannot be inferred from such models: they can only hope to 
highlight those variables associated with fatigue after adjust-
ment for the presence of other covariates. The assumptions 
underlying the multiple regression analysis were tested by 
lack-of-fit testing and inspection of residuals. Statistical anal-
yses were performed using SAS JMP (V.13) Statistical Data 
Visualisation Software. Statistical significance was set at a p 
value of ≤0.05.
ResulTs
The median age of our cohort (n=608) was 64 years 
(IQR: 53–71). The median number of symptom years for 
patients was 10 years (IQR: 5–17). Most UKPSSR patients 
experienced dryness as measured by objective measures 
of dryness such as Salivary Flow and Schirmer’s Test. 
The median score on the ESSPRI scale was 5.67 (IQR: 
3.67–7.00) and the EULAR Dryness Scale (ESS) was 6 
(IQR: 4–8). The median disease activity score (ESSDAI) 
for the cohort was 3 (IQR: 1–7). While more than half 
of patients received one or more medications to manage 
their dryness symptoms, 40% of patients ranked fatigue 
or mental fatigue—rather than dryness—as the symptom 
‘most in need of improvement’. This is similar to the 
numbers ranking dryness as the most in need of improve-
ment (45%), and rather more than those ranking pain as 
the symptom most in need of improvement (15%).
Comorbidities and medications associated with drowsiness
In addition to meeting AECG classification criteria for 
Sjogren’s syndrome, patients in the UKPSSR cohort are 
an older cohort presenting with relatively complex health 
needs. The median CPS for the cohort was 6 (IQR: 3–9). 
Almost one-third of patients with pSS presented with 
one or more fatigue-related comorbidities. The most 
commonly reported comorbidity was hypothyroidism, 
see table 1.
In addition, 130 patients with pSS were prescribed a 
number of different drugs associated with drowsiness. 
The most common drowsiness-associated medications 
included antidepressants, such as citalopram (18%), 
amitriptyline (12%) and fluoxetine (11%), or analgesics 
such as tramadol (13%). Some patients took two or more 
drowsiness-associated medications, see table 2.
For information, summary statistics are reported sepa-
rately for four separate subsets of patients: (a) patients 
with comorbidities associated with drowsiness, (b) 
patients with medications associated with drowsiness, (c) 
patients with both comorbidities and medications associ-
ated with drowsiness and (d) patients with neither comor-
bidities nor medications associated with drowsiness, see 
online supplementary table S2. Note that most patients 
presented with neither comorbidities nor medications 
associated with drowsiness. While apparent differences 
between subsets must be interpreted with caution—see 
online supplementary appendix—not surprisingly, there 
were statistically significant differences in both physical 
and mental PROFAD fatigue scores for patients with 
comorbidities associated with fatigue or medications asso-
ciated with drowsiness (Kruskal-Wallis test, p<0.0001).
Models of fatigue
In order to identify variables associated with physical and 
mental fatigue, we ran multiple regression models sepa-
rately for PROFAD physical and PROFAD mental fatigue 
scores. The models included the candidate variables: age, 
sex, symptom years, anti-Ro or anti-La positivity, pain, 
dryness, Epworth Sleepiness Scale and BMI. In addition, 
we included dummy variables for comorbidities associ-
ated with drowsiness—anaemia, obesity, hypothyroidism, 
IDDM, NIDDM, coeliac disease and a diagnosis of clinical 
depression (labelled respectively, Anaemia COMORBID, 
Obesity COMORBID, Hypothyroidism COMORBID, IDD 
COMORBID, NIDD COMORBID, Coeliac COMORBID and 
Depression COMORBID). The dummy variable DROWSY 
Medications captured those patients on medications associ-
ated with drowsiness. A list of medications associated with 
drowsiness is given in the online supplementary appendix. 
In addition, the model included anxiety and depression 
scores from the HADS. Given the large number of candi-
date variables, we used a Benjamini-Hochberg correction to 
adjust the false discovery rate (p value=0.05).14 Further statis-
tical details are given in the online supplementary file. Full 
multiple regression equations for PROFAD physical and 
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Table 2 Numbers of patients prescribed drowsy 
medications. While 108 patients took one and 22 took two 
or more drowsy medications, most patients (478) took no 
drowsy medications. Of those taking one or more drowsy 
medications, citalopram, tramadol, amitriptyline, fluoxetine 
and zopiclone were the most frequently reported
Drowsy medications
Number of 
patients
None 478
CITALOPRAM 23
TRAMADOL 17
AMITRIPTYLINE 16
FLUOXETINE 14
ZOPICLONE 4
DIAZEPAM 3
DOSULEPIN 3
GABAPENTIN 3
PAROXETINE 3
BACLOFEN 2
DULOXETINE 2
IMIPRAMINE 2
MIRTAZAPINE 2
SERTRALINE 2
TEMAZEPAM 2
ZOLPIDEM 2
CARBAMAZEPINE 1
CLOMIPRAMINE 1
CLONAZEPAM 1
LAMOTRIGINE 1
LEVETIRACETAM 1
NORTRIPTYLINE 1
RISPERIDONE 1
SODIUM VALPROATE 1
CARBAMAZAPINE ESCITALOPRAM AMITRIPTYLINE 1
DIAZEPAM DOSULEPIN 1
DULOXETINE AMITRIPTYLINE CITALOPRAM 1
ESCITALOPRAM DIAZEPAM 1
GABAPENTIN FLUOXETINE 1
LAMOTRIGINE CITALOPRAM 1
TOPIRAMATE MIRTAZAPINE AMITRIPTYLINE 1
TRAMADOL AMITRIPTYLINE 1
TRAMADOL CITALOPRAM 3
TRAMADOL DOSULEPIN 1
TRAMADOL FLUOXETINE DIAZEPAM 1
TRAMADOL GABAPENTIN 1
TRAMADOL SERTRALINE LITHIUM CHLORPROMAZINE 
TEMAZEPAM
1
TRAMADOL ZOPICLONE 1
VENLAFAXINE ROPINIROLE QUETIAPINE 1
ZOLPIDEM SERTRALINE 1
ZOPICLONE AMITRIPTYLINE 1
ZOPICLONE FLUOXETINE 1
ZOPICLONE LAMOTRIGINE FLUOXETINE 1
ZOPICLONE OLANZAPINE GABAPENTIN DIAZEPAM 1
Total 608
Figure 1 Summary multiple regression charts for (A) 
PROFAD physical fatigue and (B) PROFAD mental fatigue 
scores. Log worth values indicate the relative importance 
of each variable in the model. The broken, blue, vertical 
reference line is for Log worth=2.0 equivalent to an false 
discovery rate-adjusted p value of 0.01. Note that both pain 
and depression are closely associated with both physical and 
mental fatigue. See text. BMI, body mass index; PROFAD, 
Profile of Fatigue and Discomfort.
PROFAD mental scores are presented in online supplemen-
tary table 3. These analyses are summarised in figure 1. Note 
that while there was a weak association between ESSDAI 
disease activity scores and PROFAD fatigue scores, this was 
not robust to the inclusion of other covariates, see online 
supplementary appendix.
Interestingly, pain and depression scores are correlated 
with both PROFAD physical fatigue and PROFAD mental 
fatigue scores. The physical fatigue model identified pain, 
depression, dryness and scores on the Epworth daytime 
sleepiness scale as the most important variables associ-
ated with PROFAD physical fatigue scores (all p≤0.0001). 
The mental fatigue model identified pain, depression 
and scores on the Epworth daytime sleepiness scale as the 
three most important variables associated with PROFAD 
mental fatigue scores (all p≤0.0001).
The strong association of depression on the HADS 
with both physical and mental fatigue prompted us to 
repeat the analysis with depression COMORBID recoded 
to include a new category—those patients with a HADS 
score >8 or a depression score >8. Such patients warrant 
further assessment for depression and may represent 
a subset of those patients with currently undiagnosed 
depression. Repeating the analysis, even after adjustment 
for potential undiagnosed depression, the relationships 
of pain, depression, dryness and Epworth daytime sleep-
iness scores remained statistically significant (p<0.0001).
None of the comorbidities associated with fatigue had 
a statistically significant relationship with either PROFAD 
physical or PROFAD mental scores. However, patients 
prescribed medications associated with drowsiness had 
higher PROFAD physical fatigue scores (p=0.0001).
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dIsCussIOn
Fatigue is important to patients with pss
This is the largest study to date investigating fatigue in 
patients with pSS. Our study confirms previous observations 
that fatigue is an important symptom in need of improve-
ment.15 The main objective was to report on fatigue in 
patients with pSS after separating out effects attributable to 
assignable causes such as comorbidities and medications. 
Our data suggest that while patients with pSS may present 
with complex comorbidities and medications associated 
with fatigue, these account for a relatively small proportion 
of the variation in fatigue symptoms.
Pain, depression and dryness
Fatigue symptoms are important to patients with pSS and 
there is an association between fatigue and other symp-
toms such as pain and depression.16 17 Howard Tripp et 
al18 identified pain and depression scores, in association 
with the pro-inflammatory cytokines inducible protein 
10 and interferon gamma, as the two symptoms best 
predicting fatigue groups.18
Pain is associated with both mental and physical 
fatigue.19 The origin of pain in pSS is unclear, although 
research points towards neuropathic pain being the 
most common type of pain in pSS, followed by nocicep-
tive pain.16 The relationship between pain and fatigue 
is reported in other conditions including rheumatoid 
arthritis (RA), systemic lupus erythematosus and anky-
losing spondylitis (AS).20–22 Previous research using 
anti-tumour necrosis factor inhibitors in RA suggests that 
the reductions in reported fatigue were attributable to a 
reduction in pain, rather than direct effects on fatigue 
itself23 and pain may be a mediator of fatigue. Pain can be 
modified through medications which have an association 
with drowsiness such as amitriptyline and gabapentin. 
This contribution gives a possible explanation as to why 
drowsy medications do not have a major role in predicting 
mental fatigue.
Interestingly, we found that a diagnosis of clinical depres-
sion was not associated with higher fatigue. It is possible 
that those patients with a pre-existing depression diagnosis 
have been successfully treated for their depression and 
consequently are less likely to experience fatigue. However, 
less than 5% of our cohort had a clinical diagnosis of 
depression—rather less than that for other rheumatic 
diseases24—and yet more than half presented with HADS 
scores suggesting they be screened for depression or were 
treated with antidepressants. If depression were under-re-
ported, then this might lead to an apparent association 
between depression scores and fatigue. However, the rela-
tionship between depression scores and fatigue was robust 
to the introduction of an additional classification capturing 
those patients with a potentially undiagnosed depression.
Dryness is one of the characteristic symptoms of pSS 
and we observed a strong relationship between dryness 
symptoms and physical fatigue. Dryness may be directly 
related to fatigue, or it may act as an indicator of either 
severity or disease activity. In a recent qualitative study 
of pSS fatigue, patients described experiencing ‘ocular 
fatigue’, where they experienced tiredness in their eyes, 
which for many, related to their ocular dryness symp-
toms such as feeling gritty or sore.25 High dryness scores 
may simply indicate that the disease is highly active, or 
needs to be more closely managed in the clinic. Dryness 
symptoms may be an indicator of autonomic dysfunction, 
and fatigue may be a result of autonomic dysfunction. 
In addition, dryness symptoms may be associated with 
changes in nocturnal behaviour—see below.
sleep
The Epworth Sleepiness Scale can be used as a screening 
tool to identify patients who potentially have obstructive 
sleep apnoea and other primary sleep disorders.26 We 
observed that the scores on the Epworth scale were associ-
ated both with physical and mental fatigue. This finding is 
similar to a recent study in RA, which found that both phys-
ical and mental fatigue were associated with poor sleep.27 
While there are limitations to the Epworth scale, this does 
suggest that patients with pSS be screened for sleep prob-
lems. This could include incorporating information from a 
caregiver, partner or others, using other sleep instruments, 
polysomnography and other tests with referral to special-
ists in sleep disorders. A recent review has identified that a 
range of sleep disturbances, including night awakenings, are 
common in patients with pSS.28 Troublesome sicca symp-
toms, pain and nocturia have been identified as symptoms 
which can potentially disturb sleep causing a reduction in 
sleep quality.28 Identification of specific sleep disturbances 
in this patient group is essential, and a combination of objec-
tive and subjective measures is required to identify specific 
primary sleep disorders,29 30 thereby ensuring that patients 
have access to appropriate interventions. Treatment of sleep 
disturbances in other rheumatic diseases has resulted in a 
reduction of pain, fatigue and depression.31
ReCOMMendaTIOns
Our data confirm the importance of fatigue symptoms—
both mental and physical—to patients with pSS and 
permit identification of factors contributing to fatigue 
including other comorbidities and medications associ-
ated with drowsiness. Given the wide variety of potential 
factors contributing to fatigue, we support the view that 
a multidisciplinary approach is essential for the clinical 
management of fatigue in pSS.32
 ► We observe that many patients with pSS are taking 
multiple medications and we recommend a medica-
tion review be undertaken to identify drowsy medica-
tions which could be contributing to fatigue. If these 
medications are discontinued, then a review should 
be arranged and if the fatigue does not improve, 
then treatment of comorbidities should be consid-
ered. However, as pain is a major contributor of both 
mental and physical fatigue, the contribution of 
some pain-modifying medications may be beneficial, 
despite their association with drowsiness.
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 ► Patients with pSS should be tested for common comor-
bidities which can contribute to fatigue, including 
anaemia or hypothyroidism and offered appropriate 
treatments.
 ► We recommend screening for depression and anxiety 
and offering patients appropriate interventions to 
address these symptoms. Non-pharmacological inter-
ventions (such as talking therapies) may reduce the 
need for antidepressants and anti-anxiolytics, many of 
which are associated with drowsiness.
 ► We recommend that patients undergo a more detailed 
sleep assessment in order to screen for a primary 
sleep disorder. Patients identified with conditions 
such as obstructive sleep apnoea should be offered 
assignable causes such as Continuous Positive Airway 
Pressure (CPAP) treatment.33 Interventions such as 
cognitive behavioural therapy for insomnia (CBT-I) 
are a first-line treatment for insomnia associated with 
other medical conditions34 and may prove beneficial 
to patients with pSS.28
 ► Patients with pSS should be offered appropriate pain 
management interventions. If pain is associated with 
poor sleep, then CBT-I with a pain adjunct has been 
suggested as a feasible treatment.35
 ► Finally, in the absence of good evidence to support 
effective drug treatments, fatigue interventions in 
pSS might focus on a multidisciplinary approach 
incorporating activity management, graded exercise/
activity and CBT.32
There are limitations to this study. While the PROFAD 
system is an established and well-validated tool, there is still 
a need for a good objective measure of fatigue. Though a 
sample population of 608 patients gives some assurance that 
this study is a reasonable cross section of patients in the UK, 
it would be useful to have comparative data in the future 
from other cohorts. While there was no evidence of biases 
arising from missing data, we note that data were incom-
plete for some measures and these are noted in the relevant 
tables of summary statistics. In addition, this was an obser-
vational study using cross-sectional data. We cannot infer 
causality and are only able to report associations. Prediction 
models do not imply causation.
COnClusIOns
Our data support that of others in recognising the impor-
tance of fatigue in the clinical management of patients 
with pSS.3 5 36–40 Furthermore, our analysis permits the 
identification of contributing factors—such as comor-
bidities and drowsiness-associated medications. In addi-
tion, we identified multiple factors associated with both 
physical and mental fatigue in pSS. Most notable of these 
are pain scores measured on the ESSPRI and depres-
sion scores measured on the HADS. These associations 
are robust and observed in patients with pSS even after 
adjustment for assignable causes such as other comor-
bidities and use of medications associated with drowsi-
ness. Interventions directed at managing fatigue might 
be expected to have a significant impact on the patient’s 
quality of life. We recommend that the management of 
fatigue in pSS be multidisciplinary, and personalised to 
each patient depending on potential contributors to 
what is a debilitating and complex symptom.
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